Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27,795,576
-
Total 13F shares
-
26,398,896
-
Share change
-
+8,355,075
-
Total reported value
-
$40,128,620
-
Put/Call ratio
-
568%
-
Price per share
-
$1.52
-
Number of holders
-
71
-
Value change
-
+$12,883,590
-
Number of buys
-
31
-
Number of sells
-
21
Institutional Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q3 2022
As of 30 Sep 2022,
Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) was held by
71 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
26,398,896 shares.
The largest 10 holders included
GRIFFIN ASSET MANAGEMENT, INC., VANGUARD GROUP INC, Birchview Capital, LP, ORACLE INVESTMENT MANAGEMENT INC, Alyeska Investment Group, L.P., JPMORGAN CHASE & CO, Cannell & Co., MILLENNIUM MANAGEMENT LLC, Cladis Investment Advisory, LLC, and SUSQUEHANNA INTERNATIONAL GROUP, LLP.
This page lists
72
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.